|Bid||0.00 x 3000|
|Ask||0.00 x 34100|
|Day's Range||13.75 - 13.76|
|52 Week Range||4.41 - 13.80|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
MONTREAL, Jan. 27, 2021 /CNW Telbec/ - Pomerleau is pleased to announce the appointment of Philippe Adam as Executive Vice-President and Chief Financial Officer, effective May 3, 2021.
Covis Group S.à r.l. ("Covis") today announced the completion of its acquisition of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) through the successful tender offer for all of the outstanding shares of common stock of AMAG at $13.75 per share in cash and subsequent merger. The combined organization will operate as part of the Covis Pharma Group and will be led by Covis CEO Michael Porter.
NEW YORK, NY / ACCESSWIRE / November 13, 2020 / AMAG Pharmaceuticals, Inc.